Shares of Apricus Biosciences Inc (NASDAQ:APRI) were up 9.8% on Wednesday . The stock traded as high as $2.04 and last traded at $2.02. Approximately 918,900 shares were traded during trading, an increase of 61% from the average daily volume of 569,750 shares. The stock had previously closed at $1.84.
Several analysts have weighed in on APRI shares. HC Wainwright reaffirmed a “buy” rating and set a $4.50 price objective on shares of Apricus Biosciences in a research note on Friday, November 3rd. Zacks Investment Research upgraded shares of Apricus Biosciences from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a research report on Tuesday, October 31st.
The company has a market capitalization of $32.10, a PE ratio of 3.64 and a beta of 0.43.
About Apricus Biosciences
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.